Robert Frey, MD
Interventional Pain Medicine · Ventura, CANPI 1912934779
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,925 of the $10,427 with a category attached, or 76.0%. Boston Scientific accounts for 99.2% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $7,721 and has fallen 99.2% since, to $63 in 2025.
Across 139 payments — averaging $75.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$10K
- SPR Therapeutics, Inc$68
- AbbVie$18
What the payments were for
- Consulting fees$6236%
- Speaking & faculty fees$7,92576%
- Food & beverage$1,87918%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 137 | $10,341 |
| SPR Therapeutics, Inc | 1 | $68 |
| AbbVie | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPECTRA WAVEWRITER$5,296
- PRECISION$3,360
How this compares
$10,427 in reported general payments places this provider in the 75th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 111 | $23,733 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 772 | $21,873 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 548 | $14,659 |
| OxycontinOxycodone Hcl | 14 | $13,390 |
| Pregabalin | 610 | $11,778 |
| Duloxetine Hcl | 633 | $10,214 |
| Fentanyl | 100 | $7,823 |
| Oxycodone Hcl | 363 | $6,683 |
| Morphine Sulfate ErMorphine Sulfate | 176 | $5,542 |
| Baclofen | 254 | $5,403 |
| Diclofenac Sodium | 365 | $4,096 |
| Buprenorphine | 14 | $3,995 |
| Methadone Hcl | 293 | $3,866 |
| Gabapentin | 325 | $3,723 |
| Celecoxib | 70 | $3,372 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Ventura
- Michael Verdolinla Mesa$507K
- Tim LeierRancho Mirage$449K
- Jonathan GrossmanVisalia$404K
- Kasra MaasumiRancho Santa Margarita$388K
- Andrew GermanovichRancho Mirage$333K
- David LeeYorba Linda$257K
- Standiford HelmOrange$254K
- Patrick BuchananCamarillo$219K
- Chau VuSanta Rosa$141K
- Phillip LimBuena Park$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.